Pharmaceuticals, Biotechnology and Life Sciences
Kangpu Biopharmaceuticals has completed a first-in-human phase I single ascending dose (SAD) clinical study in the United States, testing KPG-818 for the treatment of SLE and hematological malignancies.
Successful completion of Phase 2 monotherapy trial paves way for Phase 3 trials in China in early 2020 CAMBRIDGE, Mass.…
– First Topical Anti-VEGF Eye Drop to Demonstrate both Safety and Biological Response as Monotherapy in Treatment-naïve Patients with Wet…
FOSTER CITY, Calif. & MECHELEN, Belgium–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced…
FDA has granted to Boehringer Ingelheim a breakthrough therapy designation for Ofev, for Chronic Fibrosing ILDs with a Progressive Phenotype, after the study results from the Phase III testing met its primary endpoint and was recently published in the New England Journal of Medicine.
Clinical Timelines Not Impacted and $20 Million of Annualized Savings Expected SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Five Prime Therapeutics, Inc. (NASDAQ:…
Aerpio Pharmaceutical encouraged by the early safety findings and potential efficacy signal of this ongoing Phase 1b trial.
Harlan Levine, M.D., president of strategy and business ventures at City of Hope, joins the governing board of the bioscience…
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), has launched its generic version of Invega® (paliperidone) extended-release tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg.
Company to expand the use of its PROZOR implant technology by building on the success with its lead antipsychotic program…